AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20332194
Drug: 72 h
RxNorm normalized name: 72 Hour Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 h prophylactic antibiotic therapy
Trial: 6208103
Drug: Remission induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission induction treatment with Ara‐C c. inf. from the first to the eighth day plus Adr. from the first to the third day
Trial: 6208103
Drug: Remission induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remission induction treatment with Ara‐C + 6‐TG + Adr., 6 + 6 + 2 days
Trial: 6208103
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with 5 day course of Ara‐C s.c. in addition to 6‐TG, Vincristine plus Prednisone and Adriamycin
Trial: 6208103
Drug: Calf thymus
RxNorm normalized name: Calf thymus ribonuclease H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calf thymus extract (TFX‐Polfa) in addition to maintenance therapy
Trial: 31083077
Drug: AM-111 (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM-111 (0.4 mg/ml)
Trial: 31083077
Drug: AM-111 (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM-111 (0.8 mg/ml)
Trial: 30071702
Drug: Tailored communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored communication regarding patients' oral health based on health literacy levels
Trial: 22863642
Drug: High supplement
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High supplement users (≥3 formulations per day)
Trial: 18803557
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia (EMLA 5% cream)
Trial: 18036295
Drug: No anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulation or antiplatelet drugs
Trial: 11862356
Drug: Caffeine 600
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 600 mg
Trial: 10203414
Drug: Cyclic group
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic group (800 mg twice daily of oral clodronate for 2 weeks every 3 months for the first 12 months)
Trial: 10203414
Drug: Continuous group
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous group (400 mg of clodronate once daily for the second 12 months)
Trial: 108461
Drug: Nitroglycerin (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (0.6 to 6.0 mg/h, mean 2.3 mg/h) over 48 hours
Trial: 108461
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no specific therapy)
Trial: 26914336
Drug: Tzu-Yun Ointment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tzu-Yun Ointment (TYO)
Trial: 26914336
Drug: Topical Steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Steroids (TS)
Trial: 22095398
Drug: Mericitabine (RG7128)
RxNorm normalized name: Emtricitabine
DrugBank: Mericitabine (DB12045)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mericitabine (RG7128) 750 mg administered bid
Trial: 22095398
Drug: Mericitabine (RG7128)
RxNorm normalized name: Emtricitabine
DrugBank: Mericitabine (DB12045)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mericitabine (RG7128) 1500 mg administered bid
Trial: 22095398
Drug: Mericitabine (RG7128)
RxNorm normalized name: Emtricitabine
DrugBank: Mericitabine (DB12045)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Mericitabine (RG7128) administered qd
Trial: 19566665
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg twice weekly re-treatment
Trial: 19566665
Drug: Etanercept re-treatment
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Etanercept re-treatment
Trial: 323316
Drug: Kanamycin gel
DrugBank: Kanamycin (DB01172)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Kanamycin gel treatment for one week before and after dental restorations
Trial: 24751323
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel treatment
Trial: 28605468
Drug: X358 (0.1-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X358 (0.1-9 mg/kg)
Trial: 28605468
Drug: X358 (3-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: X358 (3-9 mg/kg)
Trial: 21281461
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (Group CBT) sessions
Trial: 9005797
Drug: Ofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (200 mg twice a day for 3 to 5 days, followed by oral use of the same dosage for 3 to 5 days)
Trial: 9005797
Drug: Ofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (400 mg once a day for 3 to 5 days)
Trial: 9005797
Drug: Ofloxacin (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (same dosage as above for 10 days)
Trial: 7047171
Drug: Phenoperidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoperidine (2 mg i.v.)
Trial: 7047171
Drug: Diazepam (t
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (t mg i.v.)
Trial: 31547291
Drug: Sugar beet
RxNorm normalized name: Sugar beet pollen
DrugBank: Beet (DB10640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar beet pectin (15 g/day)
Trial: 25146586
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg, open-label, every 4 weeks for up to 7 years (total of 91 doses)
Trial: 22029576
Drug: Physostigmine ointment
RxNorm normalized name: physostigmine Ophthalmic Ointment
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine ointment after phacoemulsification
Trial: 22029576
Drug: Physostigmine ointment
RxNorm normalized name: physostigmine Ophthalmic Ointment
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine ointment
Trial: 19452483
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment with atorvastatin (maximum 80 mg/d)
Trial: 19452483
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (continuation of baseline lipid-lowering therapy)
Trial: 16721618
Drug: Preoperative intraarticular
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Trial: 16721618
Drug: Postoperative intraarticular
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative intraarticular anesthesia (0.1 mg Fentanyl + 8 ml Bupivacain 0.5%)
Trial: 16721618
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block (20 ml Prilocain 1% + 20 ml Bupivacain 0.5%)
Trial: 16036026
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockade
Trial: 16036026
Drug: Aldosterone receptor
RxNorm normalized name: Aldosterone receptor site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone receptor blockade
Trial: 7645915
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (enoxaparin) 40 mg once daily, starting 12 hours preoperatively for 10 days
Trial: 7645915
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH) 5000 IU twice a day subcutaneously, starting two hours before operation for 10 days
Trial: 30325305
Drug: 300mg of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg of daily oral aspirin
Trial: 28075064
Drug: Nebivolol-valsartan SPC
RxNorm normalized name: nebivolol / valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol-valsartan SPC (5/80 mg/d)
Trial: 28075064
Drug: Nebivolol or
RxNorm normalized name: nebivolol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol or valsartan monotherapy
Trial: 28075064
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (including SPCs, nebivolol, valsartan)
Trial: 24296958
Drug: Dexmedetomidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.3 μg/kg)
Trial: 17215657
Drug: Olmesartan 40
RxNorm normalized name: HCTZ 25/OLMESARTAN 40MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan 40 mg/d
Trial: 17215657
Drug: Olmesartan/HCTZ 40/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/HCTZ 40/12.5 mg/d
Trial: 17215657
Drug: Olmesartan/HCTZ 40/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/HCTZ 40/25 mg/d
Trial: 11488316
Drug: High initial
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High initial dose of budesonide (800 microg b.i.d)
Trial: 11488316
Drug: Standard initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard initial dose of budesonide (200 microg b.i.d)
Trial: 9590413
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg or 40 mg (duodenal and gastric ulcer protocols)
Trial: 9590413
Drug: Rabeprazole (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (all doses)
Trial: 7921757
Drug: Efamol Marine
RxNorm normalized name: marine non-gelling gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efamol Marine (12 capsules daily for 9 months)
Trial: 7921757
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 capsules daily for 9 months)
Trial: 3246170
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular dose of ceftriaxone 50 mg/kg
Trial: 3246170
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of amoxicillin 12.5 mg/kg t.i.d.
Trial: 30101580
Drug: R.O.C.S. medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R.O.C.S. medical minerals gel (group E3)
Trial: 26653722
Drug: Topical NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical NSAID treatment on the day of surgery in the femtosecond laser group
Trial: 26653722
Drug: Topical NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical NSAID treatment on the day of surgery in the conventional cataract surgery group
Trial: 22548378
Drug: Positive Family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive Family Interaction Therapy (PFIT) - 12 weeks of individual child CBT plus 6 sessions of family treatment
Trial: 22548378
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (ST) - 12 weeks of individual child CBT with weekly parent check‐ins and psychoeducation
Trial: 21469215
Drug: Add-on mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add-on mirtazapine 30 mg during a 6-week double-blind phase
Trial: 18798752
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (TAC) with onion extract gel
Trial: 16391903
Drug: Lifestyle modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle modification plus Metformin (LSM + MET)
Trial: 10965417
Drug: Herbal combination
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal combination therapy comprising crataegus and camphor (Korodin Herz‐Kreislauf‐Tropfen)
Trial: 10965417
Drug: Placebo identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in colour and taste to the active treatment
Trial: 1281728
Drug: Terazosin 10
RxNorm normalized name: terazosin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 10 mg
Trial: 30443999
Drug: Ticagrelor 10
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 10 mg
Trial: 20084109
Drug: Leucovorin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin (1 mg/kg daily for 12 months)
Trial: 20084109
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mg/kg daily for 12 months)
Trial: 20084109
Drug: Leucovorin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin with concomitant thyroxin treatment
Trial: 20084109
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with concomitant thyroxin treatment
Trial: 14740095
Drug: Gadodiamide administration
RxNorm normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadodiamide administration at 3 T
Trial: 14740095
Drug: Cumulative triple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative triple-dose 3 T images
Trial: 14740095
Drug: Cumulative triple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative triple-dose 1.5 T images
Trial: 9581302
Drug: Ampicillin-sulbactam (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin-sulbactam (100 mg/kg per day for 5 days)
Trial: 7800155
Drug: Moclobemide (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (up to 300 mg per day)
Trial: 3050906
Drug: Diflunisal 500
RxNorm normalized name: diflunisal 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 500 mg (single dose)
Trial: 3050906
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg (2-dose regimen)
Trial: 3050906
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg (2-dose regimen)
Trial: 26514619
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid (ALA) with sodium ferrous citrate (SFC) (100 and 115 mg/day)
Trial: 22160495
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (2 g/day for 8 weeks)
Trial: 21056806
Drug: Preemptive lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive lidocaine 4 mL mixed with propofol 20 mL
Trial: 21056806
Drug: Preemptive lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preemptive lidocaine 4 mL mixed with etomidate 20 mL
Trial: 21056806
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment with lidocaine 4 mL mixed with propofol 20 mL
Trial: 21056806
Drug: Simultaneous treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous treatment with lidocaine 4 mL mixed with etomidate 20 mL
Trial: 16297689
Drug: 0.75 mg/mL
RxNorm normalized name: digoxin 0.75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/mL rhBMP-2/ACS
Trial: 16297689
Drug: 1.50 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.50 mg/mL rhBMP-2/ACS
Trial: 7594348
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg q.d. plus ampicillin 500 mg b.i.d.
Trial: 7594348
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg b.i.d. plus ampicillin 500 mg b.i.d.
Trial: 471256
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (31 patients, uniform intervention on primary risk factors and medical therapy)
Trial: 22522672
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg single dose (group B)
Trial: 22522672
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg every other day for 15 days (group C)
Trial: 19221595
Drug: Topical paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical paromomycin (PR) with methylbenzethonium chloride (MBCL)
Trial: 19221595
Drug: Topical paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical paromomycin (PR)
Trial: 19221595
Drug: Parenteral paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral paromomycin (PR)
Trial: 19221595
Drug: Topical or
RxNorm normalized name: aloe vera topical oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical or parenteral paromomycin (PR)
Trial: 9823137
Drug: Corticosteroid-antibiotic solution
RxNorm normalized name: antibiotics in combination with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid-antibiotic solution
Trial: 7704924
Drug: Trivalent oral
RxNorm normalized name: poliovirus vaccine, live, trivalent oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent oral poliovirus vaccine (TOPV) given at birth, 6 weeks, 10 weeks, and 14 weeks after birth
Trial: 7704924
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group omitted the dose at birth
Trial: 2653972
Drug: Loperamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (2 mg capsules, two on entry and one after each unformed stool up to a maximum of eight per day)
Trial: 373661
Drug: Terbutaline sulfate,
RxNorm normalized name: Terbutaline Sulfate, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline sulfate, 5 mg
Trial: 373661
Drug: Ephedrine sulfate,
RxNorm normalized name: EPHEDrine Sulfate, 25 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine sulfate, 25 mg
Trial: 373661
Drug: Aminophylline, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline, 400 mg
Trial: 31875646
Drug: GFRAL-antagonist antibody
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFRAL-antagonist antibody
Trial: 26466219
Drug: Morphine (0.1mg/kg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.1mg/kg, max 5mg) associated with midazolam (0.2mg/kg, max 10mg)
Trial: 24416905
Drug: Manipulation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation of Traditional Chinese Medicine (TCM)
Trial: 15240190
Drug: IFN beta-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN beta-1b standard dose (250 microg every other day)
Trial: 8772552
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (100-400 ng/kg-day ethinyl estradiol)
Trial: 25573347
Drug: Garlic powder
RxNorm normalized name: Garlic Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic powder tablet (1200 µg allicin/tab) twice daily for 3 months
Trial: 19274696
Drug: Benzyl benzoate
RxNorm normalized name: Benzyl Benzoate
DrugBank: Benzyl benzoate (DB00676)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzyl benzoate lotion
Trial: 11028944
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.2 mg at pH 4.0
Trial: 11028944
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.2 mg at pH 7.0
Trial: 11028944
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.2 mg at pH 9.0
Trial: 11028944
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.4 mg at pH 4.0
Trial: 11028944
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.4 mg at pH 7.0
Trial: 11028944
Drug: Scopolamine hydrobromide
RxNorm normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scopolamine hydrobromide 0.4 mg at pH 9.0
Trial: 9200654
Drug: Lisinopril 10-20
RxNorm normalized name: lisinopril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10-20 mg/day